Lawson Kroeker Investment Management Inc. NE Invests $7.01 Million in Enovis Co. (NYSE:ENOV)

Lawson Kroeker Investment Management Inc. NE bought a new position in Enovis Co. (NYSE:ENOV - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 125,190 shares of the company's stock, valued at approximately $7,013,000. Enovis accounts for approximately 1.4% of Lawson Kroeker Investment Management Inc. NE's investment portfolio, making the stock its 26th biggest holding. Lawson Kroeker Investment Management Inc. NE owned 0.23% of Enovis as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio boosted its stake in shares of Enovis by 48.3% during the third quarter. Public Employees Retirement System of Ohio now owns 65,916 shares of the company's stock valued at $3,476,000 after purchasing an additional 21,479 shares during the period. Tributary Capital Management LLC boosted its position in Enovis by 14.9% during the 4th quarter. Tributary Capital Management LLC now owns 292,626 shares of the company's stock valued at $16,393,000 after buying an additional 37,858 shares during the period. GSA Capital Partners LLP bought a new stake in Enovis in the 3rd quarter worth $1,339,000. PNC Financial Services Group Inc. increased its position in shares of Enovis by 174.4% in the third quarter. PNC Financial Services Group Inc. now owns 7,688 shares of the company's stock valued at $405,000 after acquiring an additional 4,886 shares during the period. Finally, Prudential PLC increased its position in shares of Enovis by 10.5% in the third quarter. Prudential PLC now owns 5,448 shares of the company's stock valued at $287,000 after acquiring an additional 518 shares during the period. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Stock Down 0.3 %

Shares of NYSE ENOV traded down $0.17 during mid-day trading on Thursday, hitting $59.78. 335,174 shares of the stock traded hands, compared to its average volume of 451,468. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -98.00 and a beta of 1.97. The stock has a fifty day moving average price of $60.67 and a 200-day moving average price of $55.17. Enovis Co. has a 52 week low of $43.04 and a 52 week high of $66.14. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.16 and a current ratio of 2.43.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.76 by $0.03. The firm had revenue of $455.00 million for the quarter, compared to analysts' expectations of $444.34 million. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. The company's quarterly revenue was up 11.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.72 EPS. Research analysts anticipate that Enovis Co. will post 2.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. UBS Group initiated coverage on shares of Enovis in a report on Monday, January 22nd. They set a "buy" rating and a $75.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and issued a $82.00 price objective on shares of Enovis in a research report on Wednesday. Canaccord Genuity Group boosted their target price on Enovis from $73.00 to $75.00 and gave the company a "buy" rating in a research note on Friday, February 23rd. Wells Fargo & Company raised their price target on Enovis from $73.00 to $79.00 and gave the stock an "overweight" rating in a research note on Friday, February 23rd. Finally, Stephens initiated coverage on shares of Enovis in a research report on Tuesday, February 13th. They set an "overweight" rating and a $72.00 price objective on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $75.43.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.